Adoption of 3D printing technology and smart patches will likely be a prevalent trend in the transdermal medical patch Market
According to our new research study on “Transdermal medical patch Market –Global Analysis and Forecast – by Type, Application, and Distribution Channel,” the transdermal medical patch market size is expected to reach US$ 10,799.74 million by 2028 from US$ 8,247.21 million in 2022; it is estimated to record a CAGR of 4.0% from 2023 to 2028. The report highlights the trends prevalent in the global transdermal medical patch market, and the drivers and deterrents pertaining to transdermal medical patch market growth. The market growth is mainly attributed to factors such as increasing prevalence of chronic diseases and growing consumption of tobacco. However, the recalls of transdermal medical patches due to drug failure hinder the transdermal medical patch market growth.
The transdermal drug administration route is novel and one of the reliable means of sustained drug delivery. With significant research being carried out in this field and increasing interest of researchers in this form of drug delivery, the number of transdermal patches reaching the marketplace is expected to rise sharply. Transdermal patches have attracted attention for decades and were used to deliver drugs such as nicotine, fentanyl, nitroglycerin, and clonidine to treat various diseases or conditions. Recently, these patches have been explored to deliver biologics in various applications. For example, smart patches are equipped with sensors and other technologies to monitor patient conditions and adjust drug delivery accordingly. In January 2023, a leading Swansea University scientist developed a new 'smart patch' to detect proinflammatory biomarkers of neurodegenerative diseases such as Parkinson's and Alzheimer's using microneedle technology. These smart patches comprise arrays of tiny needles (microneedles) designed to break the skin barrier in a minimally invasive manner and monitor the biomarkers of clinical significance. They can be self-administered for point-of-care diagnosis at general practices or at home. This innovative research can potentially change the landscape of early neurodegenerative disease detection.
According to a study titled "A smart hydrogel patch with high transparency, adhesiveness, and hemostasis for all-round treatment and glucose monitoring of diabetic foot ulcers," published in 2022, scientists have developed an intelligent patch to monitor and treat diabetic foot ulcers. This system is fabricated from conductive hydrogel patches with an ultra-high transparency polymer network. Highly transparent conductive hydrogel patches can be used to visually monitor wound healing status, promote hemostasis, improve cell-to-cell communication, prevent wound infection, promote collagen deposition, and improve vascularity. This smart patch can monitor chronic wound dressings and treat wounds simultaneously.
Researchers are using 3D printing technology to create customized transdermal patches (e.g., a 3D-printed patch for wound healing) tailored as per patient's needs. In a study by Jang et al. titled "Gelatin Methacrylate Hydrogel for Tissue Engineering Applications—A Review on Material Modifications," published in 2022, gelatin methacrylate (GelMA) was tested as a viable option with tunable physical properties. GelMA hydrogel incorporating a vascular endothelial growth factor (VEGF)-mimicking peptide was successfully printed using a 3D bio-printer due to the hydrogel inks' shear-thinning properties. The 3D structure of the hydrogel patch had high porosity and water absorption properties. Slowly released from hydrogel patches, VEGF peptide can promote cell viability, proliferation, and tubular structure formation, indicating that the 3D Gel-MA-VEGF hydrogel patch can be used for wound dressing.
According to an article titled "3D-Printed Products for Topical Skin Applications: From Personalized Dressings to Drug Delivery, "published by the National Library of Medicine in November 2021, Lim et al. reported the use of 3D-printed personalized patches that conform to the skin surface for Acetyl-hexapeptide 3 (AHP-3) delivery. In this study, two liquid monomers—polyethylene glycol diacrylate (PEGDA) and vinylpyrrolidone (VP)—in different proportions were used to improve the mechanical strength, polymerization rate, and swelling rate of the final polymer. Optimal drug loading on the resin indicated that AHP-3 remained stable throughout the manufacturing process and had no effect on the physical properties of the final polymer. Using a 3D scanned facial model, a personalized patch was designed in computer-aided design software and fabricated in optimized resin using a digital light processing 3D printer. In vitro characterization of the prepared transdermal patches showed their ability to penetrate human cadaver skin, and they remained intact after compression. This is the first study demonstrating personalized patches made using photopolymers and may be a novel approach to improve the transdermal delivery of drugs for effective wrinkle management.
Thus, the adoption of 3D printing technology and smart patches will likely be a prevalent trend in the market over the coming years.
North America is leading the global transdermal medical patch market due to rising number of patients suffering from chronic conditions such as cardiovascular disease, diabetes, chronic pain conditions, and other chronic diseases is driving the demand for effective and convenient treatment options are the key factors propelling the market for transdermal medical patch. Medical patches offer a noninvasive and patient-friendly approach to delivering medication and managing symptoms associated with these chronic conditions. Ongoing advancements in patch technologies such as improved transdermal drug delivery systems (TDDS), wearable sensors, and flexible electronics contribute to the growth of the transdermal medical patch market. Also, growing trend of personalized medicines, where treatments are tailored to individual patients, has boosted the development of medical patches that offer controlled and targeted drug delivery. This customization allows for better patient outcomes and improved therapeutic efficacy. For instance, in 2020, Reddy's Laboratories launched an Authorized Generic Version of NitroDur (nitroglycerin) Transdermal Infusion System in the US market. With the growing emphasis on home healthcare and remote patient monitoring, medical patches offer a convenient solution for delivering medications and monitoring vital signs outside traditional healthcare settings. The transdermal medical patches market in the US is influenced by factors such as the increasing prevalence of chronic diseases, rising technological advancements, and growing focus on personalized medicines.
Hisamitsu Pharmaceutical Co Inc, Medline Industries LP, Johnson & Johnson, Novartis AG, Teva Pharmaceutical Industries Ltd, UCB SA, Viatris Inc, Endo Pharmaceuticals Inc, Boehringer Ingelheim International GmbH, and Corium, LLC are among the prominent players operating in the transdermal medical patch market. These players are focused on organic and inorganic growth strategies to sustain their position in the transdermal medical patch market. in September 2022, Corium, Inc launched ADLARITY (donepezil transdermal system) and is available for prescription in the U.S. for treating patients with mild, moderate, or severe dementia of Alzheimer's type.
The report segments the global transdermal medical patch market as follows:
Based on type, the transdermal medical patch market is segmented into matrix, reservoir, single-layer drug-in-adhesive, multi-layer drug-in-adhesive, and vapour patch. Based on application, the transdermal medical patch market is segmented into pain management, neurologic conditions, nicotine cessation, cardiovascular disorders, hormonal therapy, and others. By distribution channel, the transdermal medical patch market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. By geography, the transdermal medical patch market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com